Scientists uncover ‘very detailed map’ of an enzyme target for rare metabolic disease

lysine structure
“We have this very detailed map now of what the whole protein looks like, which will help us in our efforts to try to develop a small molecule drug against this protein,” lead study author Michael Lazarus, Ph.D., said. (iStock/Getty Images)

For some rare genetic diseases, the problem isn't a missing protein but the buildup of toxic molecules that the body can no longer clear away.

In a recent study published in Science Advances, a group of researchers from Mount Sinai identified the crystal structure of an upstream enzyme in a rare genetic disease, glutaric aciduria type 1 (GA1). By understanding the structure of the enzyme, drugmakers could now potentially develop small molecule drugs to target this enzyme for the treatment of rare genetic inborn errors in metabolism.

GA1 is a rare genetic neuro-metabolic disease characterized by macrocephaly, or larger-than-average head size, and low muscle tone. Due to symptoms often not being apparent right at birth, this disease is typically tested for in newborn screening panels. If caught early, the disease can be managed by reducing lysine intake in the diet, but children are still prone to encephalopathic crises and permanent neural damage.

The disease is caused by deficiencies in the GCDH gene, which codes for an enzyme responsible for breaking down amino acids such as lysine that are then broken down further into glutaric acid. Without this enzyme, the body can experience a buildup of glutaric acid, which becomes toxic to the brain, causing the symptoms seen in GA1.

“If you inhibit an enzyme upstream of the pathway, you can prevent buildup of these toxic metabolites that accumulate because of the GCDH deficiencies,” Michael Lazarus, Ph.D., associate professor of pharmacological sciences at the Icahn School of Medicine and lead author on the study, told Fierce. This informed his team's decision to target and understand the first enzyme in this pathway, called alpha‑aminoadipic semialdehyde synthase (AASS).

AASS is responsible for breaking down lysine, acting upstream of a potentially defective GCDH enzyme. The idea of targeting AASS—or any enzyme upstream to prevent toxic buildup seen in inborn errors of metabolism—is called substrate reduction therapy.

“A lot of these genetic diseases lead to a buildup of toxic intermediates,” Lazarus said. “If you can inhibit an enzyme that's making some of these metabolites that are building up, then you can prevent them from building up in the first place.”

In the study, Lazarus and his team purified the full-length AASS protein and imaged it using a specialized microscopy technique called cryogenic electron microscopy, which flash-freezes biological samples and creates high-resolution 3D images of their structures.

“We have this very detailed map now of what the whole protein looks like, which will help us in our efforts to try to develop a small molecule drug against this protein,” Lazarus added.

The goal, Lazarus explained, would be to target the AASS enzyme to regulate the downstream pathway and prevent the buildup of glutaric acid. In 2023, he was a part of a team that published a case study on a child with a mutation in the AASS enzyme who did not need any therapeutic interventions, giving hope for the safety of pursuing this target with a small molecule.

Other companies have been using substrate reduction therapy for treatment of rare genetic disorders, too: Alnylam’s lumasiran targets the mutation that leads to an excess production of a compound called oxalate, which causes recurrent kidney stones and leads to end-stage kidney disease in primary hyperoxaluria type 1. 

And Moderna is developing several mRNA therapies to replace missing enzymes needed to break down certain proteins and fats in genetic disorders such as propionic acidemia and methylmalonic acidemia.